sangamo therapeutics interview
Our partnerships with leading global pharmaceutical companies are helping speed our mission by extending the reach of our technology and expertise. Renal Transplant Rejection Dosed the second patient in the Phase 1/2 STEADFAST study; progressed clinical activities in preparation for patient three. Sangamo is a genomic medicine company that seeks to help millions of people who suffer from severe diseases for which today's medicine can only offer symptom management at best. Management is very accessible. The average Sangamo Therapeutics salary ranges from approximately $88,067 per year for a Research Associate II to $240,483 per year for an Associate Director. This press release contains forward-looking statements regarding our current expectations. We believe that this non-GAAP financial measure, when considered together with our financial information prepared in accordance with GAAP, can enhance investors and analysts ability to meaningfully compare our results from period to period and to our forward-looking guidance, and to identify operating trends in our business. This has been a year marked by progress across our pipeline. Sickle cell disease Dosed sixth patient, the second with a product candidate manufactured using improved methods; Phase 3 planning progresses. Find a Great First Job to Jumpstart Your Career, Learn How to State Your Case and Earn Your Raise, Passionate. Apr 28, 2022 - Principal Research Associate, May 10, 2022 - Senior Development Engineer, Sangamo Therapeutics has an overall rating of 4.2 out of 5, based on over 55 reviews left anonymously by employees. Based on 2 interviews. Technical assay related questions? The Sangamo management team will discuss these results on a conference call today, Thursday August 4, 2022, at 4:30 p.m. Eastern Time. Based on 2 interviews. Each step toward the possibility of eliminating the need for frequent, life-long treatment for the patients and families affected by debilitating disease is exciting. Gene editing is a very compelling concept for physicians. Why Sangamo? Consolidated net loss for the third quarter ended September 30, 2022 was $53.2 million, or $0.34 per share, compared to a net loss of $47.7 million, or $0.33 per share, for the same period in 2021. I interviewed at Sangamo Therapeutics (San Francisco, CA) in Aug 2020. Duties of the advertised position and the involved project. Candidates give an average difficulty score of 2.8 out of 5 (where 5 is the highest level of difficulty) for their job interview at Sangamo Therapeutics. Get started with your Free Employer Profile. Sangamo Therapeutics, Inc. Careers Website www.sangamo.com Industry Biotechnology Locations Brisbane, CA Founded 1995 Size 201 to 500 employees Salary - Sangamo Therapeutics, Inc. I applied through a recruiter. Pfizer advised us that it continues to anticipate resuming the dosing of additional patients in the Phase 3 AFFINE trial of giroctocogene fitelparvovec, an investigational gene therapy we are developing with Pfizer for patients with moderately severe to severe hemophilia A, in the third quarter of 2022. We expect to present additional clinical updates from the STAAR study, including the first data from the expansion cohort, in the first half of 2023. Presented seven posters and one oral presentation at ASGCT on. Louise Wilkieir@sangamo.com Revenues for the third quarter ended September 30, 2022 were $26.5 million, compared to $28.6 million for the same period in 2021. This report was sent to Briefing.com subscribers earlier today. Employees also rated Sangamo Therapeutics 4.1 out of 5 for work life balance, 4.5 for culture and values and 3.8 for career opportunities. Dosing of this second patient is expected later in the third quarter of 2022. Glassdoor has millions of jobs plus salary information, company reviews, and interview questions from people on the inside making it easy to find a job thats right for you. This rating has been stable over the past 12 months. ET to review its fourth quarter and full year 2022. Fantastic, Actual results may differ materially from those projected in these forward-looking statements due to the risks and uncertainties described above and other risks and uncertainties that exist in the operations and business environments of Sangamo and our collaborators. Minimum 15 minutes delayed. They are not authored by Glassdoor. I interviewed at Sangamo Therapeutics. Once registered, participants will be given the option to either dial into the call with the number and unique passcode provided or to use the dial-out option to connect their phone instantly. Skip to main navigation Science Overview Zinc Finger Cell Therapy Genome Regulation Bioethics The decrease of $2.1 million in revenues was primarily attributable to a decrease of $1.9 million and $1.6 million related to our collaboration agreements with Novartis and Biogen respectively, and a decrease of $1.1 million due to the termination of our collaboration agreement with Sanofi. "We made meaningful progress advancing our clinical-stage programs in the second quarter," said Sandy Macrae, Chief Executive Officer of Sangamo. Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and third quarter 2022 financial results. We expect to dose two additional patients imminently, and have multiple patients in screening, including both male and female candidates. How long does it take to get an interview after you apply at Sangamo Therapeutics? 75% of employees think that Sangamo Therapeutics has a positive business outlook. Winning Companies champion board diversity by having 20% or more of their board seats held by women. (unaudited; in thousands, except per share data), View source version on businesswire.com: https://www.businesswire.com/news/home/20221103005505/en/, Investor Relations & Media Inquiries Working in the company was very fun, I learned a lot about the technology that the company uses and about the different methodologies and techniques Sangamo has. Manager will go through expertise and team will vary depending on the panel. A replay will be available following the conference call, accessible under Events and Presentations. Conference Call and Webcast Scheduled for 4:30 p.m. Eastern Time BRISBANE, Calif. --(BUSINESS WIRE)--Feb. 22, 2023-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and fourth quarter and full year 2022 financial results. Find a Great First Job to Jumpstart Your Career, Getting a Job Is Tough; This Guide Makes it Easier, Climb the Ladder With These Proven Promotion Tips, A Guide to Negotiating the Salary You Deserve. All five patients who began the dose escalation pha. Due to the split at Richmond and Brisbane, there was confusion on which site to interview. Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and second quarter 2022 financial results. We were proud to present promising updated preliminary data from our wholly owned Fabry study, to resume our partnered Hemophilia A pivotal trial, and to continue dosing in our renal transplant rejection and sickle cell studies. Salary expectation. Changes wont be saved until you sign up for an Enhanced Profile subscription. Interview experience. Sangamo uses its deep scientific expertise and proprietary zinc finger technology to create genomic cures for patients suffering from severe diseases for which todays medicine can only offer symptom management at best. Great science and robust pipelines. Candidates applying for Contractor had the quickest hiring process (on average 1 day), whereas Project Manager roles had the slowest hiring process (on average 120 days). View source version on businesswire.com: https://www.businesswire.com/news/home/20220804005384/en/, Louise Wilkieir@sangamo.com A change of -17% or more over 10 trading days is a 9% . Cash, cash equivalents and marketable securities. We are passionate about our science and driven by the purpose it serves. I interviewed at Sangamo Therapeutics (San Francisco, CA) in Aug 2020. Good, great, fine, virtual, lovely. Guided by Science. We are engaging in pivotal study-enabling activities in two of our clinical stage programs and are preparing to complete dosing of the first cohort in our TX200 program, which recently received Orphan Medicinal Product Designation from the European Commission. It was then followed by individual interviews with different members of the team, To get a job at Sangamo Therapeutics, browse, Overall, 89% of employees would recommend, Work Here? 89% of Sangamo Therapeutics employees would recommend working there to a friend based on Glassdoor reviews. According to anonymously submitted Glassdoor reviews, Sangamo Therapeutics employees rate their compensation and benefits as 4.0 out of 5. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Candidates interviewing for Project Manager Biotech and Research Intern rated their interviews as the hardest, whereas interviews for Project Manager and Bioinformatics Analyst I roles were rated as the easiest. Our goal is to develop a wholly owned genomic medicine portfolio, which we fund via our collaborations with blue-chip biopharmaceutical partners, which have already brought in $815M in upfronts and milestones with billions in potential milestone payments. Good people, culture, benefits and great pipeline projects. Employees rate Sangamo Therapeutics 4.2 out of 5 stars based on 55 anonymous reviews on Glassdoor. We expect to present updated data from the Phase 1/2 ALTA study via a poster presentation at the ASH Annual Meeting in December. This is based on anonymous employee . These increases were partially offset by reimbursement of certain research and development expenses by Sanofi under the termination agreement. Recruiter set up the interview. Common stages of the interview process at Sangamo Therapeutics according to 17 Glassdoor interviews include: Find a Great First Job to Jumpstart Your Career, Stand Out From the Crowd With the Perfect Cover Letter, How to Prepare for Your Interview and Land the Job. Nothing striking about this particular process. Sangamo Therapeutics saw global potential for TxCell's lead candidate TX200 as the anchor of a pipeline of chimeric antigen receptor . Background and experience. See 1 answer. Sangamo (SGMO) delivered earnings and revenue surprises of 11.11% and 0.83%, respectively, for the quarter ended December 2022. Brisbane, California, November 16, 2022 Dosing has resumed in the Phase 3 AFFINE study evaluating giroctocogene fitelparvovec, an investigational gene therapy for patients with moderately severe to severe hemophilia A. Dosing resumed on November 10, 2022. February 27, 2023 9:47 am. Since the beginning of the second quarter, we have raised approximately $43.1 million in net proceeds under our previously announced at the market offering program. Company seemed to have an outdated and rigid mindset. Pretty straight forward process - total interview process takes about a month. My three times follow-up with two different HR reps was left unanswered. In the third quarter, we continued to advance our clinical trials and preclinical activities while maintaining fiscal discipline and operational excellence, said Sandy Macrae, Chief Executive Officer of Sangamo. Tell me a little about your self. No post about Sangamo Therapeutics, Inc. yet, Hemophilia Market to Showcase Robust Growth in the Upcoming Year to 2032 | MobileODT, Gals Bio Ltd, DiagnoseSt, Global mRNA Vaccine Market Size And Forecast | Argos Therapeutics BioNTech AG, CureVac AG, eTheRNA Immunotherapies, Ethris GmbH, Incellart, Moderna Sangamo Therapeutics Tiba Biotech, Translate Bio, Inc. Sioux City Catholic Globe, We don't have enough salaries for A strategic focus on serious conditions with high unmet need and where our technology has the potential to deliver for patients guides us. Participants should register for, and access, the call using this link. How do employees rate the business outlook for Sangamo Therapeutics? I had 3 phone/Zoom interviews including with HR and the hiring managers. Subscribe to Yahoo Finance Plus to view Fair Value for SGMO. - Sustained, elevated expression of alpha-galactosidase A (-Gal A) activity observed in 13 patients for over two years for the longest treated patient as of cutoff date. Why Sangamo? Sangamo Therapeutics, Inc. yet, Randomly selected from some of the most viewed reviews. Phase 3 study design, enabling activities and manufacturing readiness are in progress. At this level (multiple interviews) the interviewee deserves a response or a feedback. Sangamo is a genomic medicine company that seeks to help millions of people who suffer from severe diseases for which todays medicine can only offer symptom management at best. - Achieved 78% globotriaosylceramide (Gb3) substrate clearance at 6-months and 77% reduction in urine podocyte loss in one of, BRISBANE, Calif. --(BUSINESS WIRE)--Feb. 21, 2023-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company is scheduled to hold a conference call on Wednesday, February 22, 2023 at 4:30 p.m. The hiring process at Sangamo Therapeutics takes an average of 31 days when considering 17 user submitted interviews across all job titles. Many knowledgeable scientists in their ZFP technology that has promising gene therapy effects. "This has been a year marked by progress across our pipeline. A pivotal data readout is estimated in late 2023 or early 2024. Sangamo plans to participate in the following events in the fourth quarter: Access links for available webcasts for these investor conferences will be available on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. This rating has improved by 1% over the last 12 months. How many more words to count? As of the November 15, 2022, supplemental cutoff date, 13 patients exhibited supraphysiological levels of -Gal A activity, sustained for over two years for the patient with the longest follow-up. Copyright 2008-2023, Glassdoor, Inc. "Glassdoor" and logo are registered trademarks of Glassdoor, Inc. Sangamo Therapeutics stock declined 17% over the last 10 trading days (2 weeks), compared to broader market (S&P500) decline of 2.5%. We completed the transition of Sanofis rights and obligations under the collaboration developing BIVV003, formerly known as. Sangamo Therapeutics has an overall rating of 4.2 out of 5, based on over 55 reviews left anonymously by employees. Recruiter set up the interview. I interviewed at Sangamo Therapeutics (New York, NY). Glassdoor has 55 Sangamo Therapeutics reviews submitted anonymously by Sangamo Therapeutics employees. This employer has claimed their Employer Profile and is engaged in the Glassdoor community. Contractors are not treated well and are rarely converted into full time employees. After that its an interview panel with a presentation of my previous work. Questions asked were appropriate and aimed at confirming the candidate possesses the required skills and would be a good fit into the company. View the full . Trial sites will begin to resume enrollment this month . However, I never hear back from them since then. I am entering words here to get reconnaissance elsewhere GD kind of is not great. Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2022 Financial Results News Release Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Showing Continued Tolerability and Sustained Elevated -Gal A Enzyme Activity in Nine Patients News Release We made meaningful progress advancing our clinical-stage programs in the second quarter, said Sandy Macrae, Chief Executive Officer of Sangamo. Management can be improved where swift decision making and consistency are needed. Our platforms have yielded multiple clinical stage programs that could provide value in the near-to-mid-term. We encourage investors to carefully consider our results under GAAP, as well as our supplemental non-GAAP financial information, to more fully understand our business. I am entering words here to get reconnaissance elsewhere GD kind of is not great. Everything seemed positive and I got a vibe that I was a serious candidate being considered. Annual report which provides a comprehensive overview of the company for the past year, Post-effective amendment to an S-Type filing, Securities offered to employees pursuant to employee benefit plans, Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results, Sangamo Therapeutics Announces Evidence of Clinical Benefit in Phase 1/2 STAAR Study in Fabry Disease, Sangamo Therapeutics Announces Fourth Quarter and Full Year 2022 Conference Call and Webcast, PHASE 3 TRIAL OF INVESTIGATIONAL GENE THERAPY FOR HEMOPHILIA A HAS RESUMED DOSING, EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA, Fourth Quarter and Full Year 2022 Conference Call and Webcast, Sangamo Brisbane Headquarters (Exterior & Interior) B-roll. This employer has claimed their Employer Profile and is engaged in the Glassdoor community. Using ground-breaking science, including our proprietary zinc finger genome engineering technology and manufacturing expertise, Sangamo aims to create new genomic medicines for patients suffering from diseases for which existing treatment options are inadequate or currently dont exist. Sangamo Therapeutics is a clinical-stage biopharmaceutical company with a robust genomic medicines pipeline. It was well thought out and carried out professionally. Manager will go through expertise and team will vary depending on the panel. https://www.openpr.com/news/2771399/hemophilia-market-to-showcase-robust-growth-in-the-upcoming-year, https://www.catholicglobe.org/global-mrna-vaccine-market-insight-size-and-forecast/. Interview difficulty. Research calls posted earlier this morning are available here. To supplement our financial results and guidance presented in accordance with GAAP, we present non-GAAP total operating expenses, which exclude stock-based compensation expense from GAAP total operating expenses. The process took 3 months. Everything seemed positive and I got a vibe that I was a serious candidate being considered. These risks and uncertainties are described more fully in our Securities and Exchange Commission filings and reports, including in our Annual Report on Form 10-K for the year ended December 31, 2021 as supplemented by our Quarterly Report on Form 10-Q for the quarter ended June 30, 2022. To learn more, visit www.sangamo.com and connect with us on LinkedIn and Twitter. The Phase 1/2 STAAR study has transitioned into the expansion phase, with the first five expansion patients dosed at the 5e13 vg/kg dose level, including the first two female patients. Really collaborative environment Great coworkers Very supportive community, Promotions based on seniority rather than merit HR does not really help solve problems, Great people, good environment, interesting science. Unorganized at best. The conference call dial-in numbers are (877) 377-7553 for domestic callers and (678) 894-3968 for international callers. The link to access the live webcast can also be found on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. Both sides asked questions and got the answers we need, and after the interview, I was even more excited to join the company. Forward-looking statements contained in this announcement are made as of this date, and we undertake no duty to update such information except as required under applicable law. ProsGreat science and robust pipelines. Enzyme replacement therapy (ERT) withdrawal was completed for an additional two patients previously dosed in the STAAR study, achieving a total of four patients to date who have successfully been withdrawn. We continue to expect non-GAAP total operating expenses, excluding estimated non-cash stock-based compensation expense of approximately $40 million, in the range of approximately $280 million to $310 million in 2022. Our platforms have yielded multiple clinical stage programs that could provide value in the near-to-mid-term. Currency in USD, Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies. Received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for BIVV003. Share your interview experience. These improved manufacturing methods have been shown in internal experiments to increase the number of long-term progenitor cells in the final product. May 26, 2020. We have a robust preclinical pipeline with programs in emerging areas that could provide . Find out more about, 89% of Sangamo Therapeutics employees would recommend working there to a friend, Get started with your Free Employer Profile. Under the general direction of the EHS Director, this role will have operational responsibility for EHS support to labs, facilities and manufacturing and shall assist with planning, establishing, implementing, and maintaining a variety of occupational health, safety, and . Sangamo Therapeutics is a genomic medicine company focused on leveraging our novel platforms and scientific expertise to advance clinical programs. There are no open jobs at Sangamo Therapeutics, Inc. currently. Sangamo plans to participate in the following events in the third quarter: Access links for these investor conferences will be available on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. Find out more about salaries and benefits at Sangamo Therapeutics. Find your private company bowl on Fishbowl, join the hottest conversation with your colleagues anonymously. We continue to actively prepare for a potential pivotal Phase 3 trial. Now many are ending their programs. I wasn't happy with the unprofessional manner. Three weeks. Management is very accessible. Company is very dedicated to patient engagement as well as inclusion and diversity.Read More. The call will also be webcast with live Q&A and can be accessed via a link on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. Phase 3 enabling activities and manufacturing readiness are in progress. Sangamo Therapeutics is a genomic medicine company focused on leveraging our novel platforms and scientific expertise to advance clinical programs. About a day or two. Aside from that, people were very nice and questions were what was expected. Benefits are great. My three times follow-up with two different HR reps was left unanswered. Overall, 89% of employees would recommend working at Sangamo Therapeutics to a friend. Was told I was a candidate in the running but they never got back to me and never responded to multiple calls or emails, Anonymous Interview Candidate in San Francisco, CA, I applied online. The process took 3 months. Barclays Gene Editing & Gene Therapy Summit. Good overall compensation and benefits. February 14, 2022. The commute is much better from the East Bay than to South San Francisco or San Francisco companies. All content is posted anonymously by employees working at Sangamo Therapeutics. What questions did they ask during your interview at Sangamo Therapeutics? Do shift work. I interviewed at Sangamo Therapeutics in Aug 2020, Nice set of interviews and great questions. This press release features multimedia. This is based on 44 anonymously submitted reviews on Glassdoor. Both sides asked questions and got the answers we need, and after the interview, I was even more excited to join the company. Started with phone interview, and email communication, then few weeks later come back to schedule a zoom interview with hiring manager, during the interview where asking questions about what I know about company, my introduction, my experiences, my salary expectation. Over 50% of the patients have been enrolled in the Phase 3 AFFINE trial. Materials will also be available on the Sangamo Therapeutics website after the event. Technical assay related questions? Non-GAAP operating expenses, which exclude stock-based compensation expense, for the third quarter ended September 30, 2022 were $73.5 million, compared to $69.1 million for the same period in 2021. Sangamo is one of the few companies pursuing programs across the spectrum of genomic medicine. Verify your email to use filters. The interview was timely, provided an overview of the company and of the role, asked the candidate to go over their relevant career trajectory and competences. Consolidated net loss for the second quarter ended June 30, 2022, was $43.2 million, or $0.29 per share, compared to a net loss of $47.2 million, or $0.33 per share, for the same period in 2021. Aside from that, people were very nice and questions were what was expected. Our scientists are leaders in the. There can be no assurance that we and our collaborators will be able to develop commercially viable products. The process took 3 days. Preliminary data showed all nine patients from the dose escalation phase exhibited sustained elevated -Gal A activity, ranging from nearly 2-fold to 30-fold of mean normal, for up to 23 months post dosing, as of the last date of measurement. Hemophilia A Announced, with Pfizer, the resumption of recruitment in the Phase 3 AFFINE trial; dosing is expected to resume shortly; pivotal data read-out expected in the first half of 2024. We have a robust preclinical pipeline with programs in emerging areas that could provide value in the mid-to-long term. I interviewed at Sangamo Therapeutics (Richmond, CA) in Jul 2019. Based on 2 interviews. Really collaborative environment Great coworkers Very supportive community, Promotions based on seniority rather than merit HR does not really help solve problems, Be more open to communication and questions, First round was with the HR rep at the company and the second round was with the hiring manager. Duties of the advertised position and the involved project. Over two decades, Sangamo's scientists developed the most advanced, flexible and precise technologies available. Key Insights Institutions' substantial holdings in Sangamo Therapeutics implies that they have significant influence Gene therapy offered hope for thousands of sickle cell disease patients. Cash, cash equivalents and marketable securities as of June 30, 2022, were $363.7 million, compared to $464.7 million as of December 31, 2021. We have excluded stock-based compensation expense because it is a non-cash expense that may vary significantly from period to period as a result of changes not directly or immediately related to the operational performance for the periods presented.